

- acute lymphoblastic leukemia—a GRAALL study. *ASH Annu Meet Abstr*. 2011;118:572.
3. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood*. 2009;114:5136-5145.

4. Rodriguez CO, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanidine. *Blood*. 2003;102:1842-1848.
5. Gökbüget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. *Blood*. 2011; 118:3504-3511.

Autologous Umbilical Cord Blood Infusion followed by Oral Docosahexaenoic Acid and Vitamin D Supplementation for C-Peptide Preservation in Children with Type 1 Diabetes

Michael J. Haller^{1,*}, Clive H. Wasserfall², Maigan A. Hulme², Miriam Cintron¹, Todd M. Brusko², Keiran M. McGrail², John R. Wingard³, Douglas W. Theriaque⁴, Jonathan J. Shuster⁴, Ronald J. Ferguson², Marianne Kozuch⁵, Michael Clare-Salzler², Mark A. Atkinson², Desmond A. Schatz¹

¹ Department of Pediatrics, the University of Florida, Gainesville, Florida

² Department of Pathology, the University of Florida, Gainesville, Florida

³ Department of Medicine, the University of Florida, Gainesville, Florida

⁴ Department of Epidemiology and Health Policy Research and the Clinical Research Center, the University of Florida, Gainesville, Florida

⁵ Department of Physiological Sciences, College of Veterinary Medicine, the University of Florida, Gainesville, Florida

Article history:

Received 21 January 2013

Accepted 15 April 2013

Key Words:

Autologous cord blood
Type 1 diabetes
Vitamin D
Docosahexaenoic acid
C-Peptide

ABSTRACT

We sought to determine if autologous umbilical cord blood (UCB) infusion followed by 1 year of supplementation with vitamin D and docosahexaenoic acid (DHA) can preserve C-peptide in children with type 1 diabetes. We conducted an open-label, 2:1 randomized study in which 15 type 1 diabetes subjects with stimulated C-peptide > .2 pmol/mL received either (1) autologous UCB infusion, 1 year of daily oral vitamin D (2000 IU), and DHA (38 mg/kg) and intensive diabetes management or (2) intensive diabetes management alone. Primary analyses were performed 1 year after UCB infusion. Treated (N = 10) and control (N = 5) subjects had median ages of 7.2 and 6.6 years, respectively. No severe adverse events were observed. Although the absolute rate of C-peptide decline was slower in treated versus control subjects, intergroup comparisons failed to reach significance ($P = .29$). Area under the curve C-peptide declined and insulin use increased in both groups ($P < .01$). Vitamin D levels remained stable in treated subjects but declined in control subjects ($P = .01$). DHA levels rose in treated subjects versus control subjects ($P = .003$). CD4/CD8 ratio remained stable in treated subjects but declined in control subjects ($P = .03$). No changes were seen in regulatory T cell frequency, total CD4 counts, or autoantibody titers. Autologous UCB infusion followed by daily supplementation with vitamin D and DHA was safe but failed to preserve C-peptide. Lack of significance may reflect small sample size. Future efforts will require expansion of specific immunoregulatory cell subsets, optimization of combined immunoregulatory and anti-inflammatory agents, and larger study cohorts.

© 2013 American Society for Blood and Marrow Transplantation.

INTRODUCTION

We previously investigated the potential for a single autologous umbilical cord blood (UCB) infusion to augment the natural history of type 1 diabetes in very young children [1-4]. Although our initial effort was not powered to demonstrate efficacy, the apparent safety of autologous UCB infusion as well as the observed postinfusion increase in peripheral blood regulatory T cell (Treg) frequency provided impetus for additional studies. Given our group's emphasis on the potential for combination therapies to provide synergy in attenuating autoimmunity and facilitating the

development of low-risk (ie, safe) therapies for young children with type 1 diabetes, we hypothesized that autologous UCB therapy could be successfully augmented by the addition of two agents with well-characterized immunomodulatory properties and potential links to type 1 diabetes pathophysiology, namely, vitamin D and docosahexaenoic acid (DHA) [5,6]. As such, we sought to perform a follow-up pilot study using this combination approach to document safety and feasibility and to generate data to guide future fully powered studies using autologous cell therapies.

METHODS

Participants

Children with type 1 diabetes older than 1 year of age and for whom autologous UCB was stored were recruited for participation (NCT00873925; FDA IND BB-11918).

Procedures

Potential subjects underwent a baseline 2-hour mixed meal tolerance test to determine eligibility [1]. Subjects with peak C-peptide > .2 pmol/L were randomized 2:1 (treatment-to-control) in an open-label manner. All

Financial disclosure: See Acknowledgments on page 1128.

* Correspondence and reprint requests: Michael J. Haller, MD, Department of Pediatrics, College of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610.

E-mail address: hallemj@peds.ufl.edu (M.J. Haller).

1083-8791/\$ — see front matter © 2013 American Society for Blood and Marrow Transplantation.

<http://dx.doi.org/10.1016/j.bbmt.2013.04.011>

Table 1
Baseline, 6-Month, and 1-Year Characteristics of Subjects Receiving Combination Therapy with UCB, Vitamin D, and DHA Compared with Control Subjects

	Treated (N = 10)				Control Subjects (N = 5)				P Comparison of Changes: 1 Yr Minus Baseline between Groups
	Baseline		P for Δ at 1 Yr		Baseline		P for Δ at 1 Yr		
	6 Mo	1 Yr	6 Mo	1 Yr	6 Mo (n = 4)	1 Yr	6 Mo (n = 4)	1 Yr	
Age, yrs	7.2	—	—	—	6.6	—	—	—	—
HbA _{1c} , %	7.1 (6.3-7.8)	6.8 (6.0-7.4)	7.3 (6.3-7.8)	.89	6.5 (6.4-6.9)	7.2 (6.6-7.5)	7.5 (7.2-7.6)	.63	.13
Insulin dose, units/kg/d	.34 (.23-.46)	.53 (.47-.64)	.10 (.06-.24)	.004	.30 (.29-.32)	.42 (.33-.63)	.65 (.57-.80)	.063	.27
AUC C-peptide, pmol/mL per 120 min	29 (.26-47)	12 (.06-.32)	.10 (.06-.24)	.004	.41 (.29-.77)	.40 (.23-.54)	.14 (.08-.25)	.063	.29
Peak C-peptide, pmol/L	.33 (.24-.52)	.19 (.09-.40)	.12 (.08-.29)	.002	.53 (.37-.86)	.48 (.28-.61)	.17 (.12-.33)	.063	.14
Vitamin D, nmol/L	78 (55-91)	122 (78-140)	96 (78-130)	.19	91 (83-99)	68 (52-120)	62 (42-83)	.063	.010
DHA, μg/mL	22 (19-29)	68 (61-84)	75 (64-79)	.004	18 (14-27)	23 (16-33)	20 (16-24)	.88	.0055
EPA, μg/mL	5.7 (4.4-6.3)	8.7 (6.3-11.1)	8.7 (7.6-10.1)	.012	4.3 (2.8-6.1)	5.4 (3.6-6.1)	5.4 (2.4-6.0)	.63	.031
DPA, μg/mL	13 (12-17)	6.8 (6.0-8.8)	8.4 (6.6-9.5)	.004	12 (10-13)	14 (13-16)	15 (11-16)	.13	.0055
Tregs, %	.47 (.18-1.04)	.21 (.13-.40)	.61 (.33-.75)	.77	.45 (.15-.64)	.20 (.10-.51)	.23 (.20-.31)	.81	.62
CD4/CD8	2.53 (1.67-2.64)	2.21 (1.75-2.63)	2.14 (1.91-2.61)	.82	1.95 (1.92-2.89)	1.85 (1.58-2.65)	1.69 (1.65-1.94)	.063	.066

DPA indicates docosapentaenoic acid; EPA, eicosapentaenoic acid. Values are medians, with interquartile ratios in parentheses.

subjects had blood drawn at baseline for complete blood count, BMP, HbA_{1c}, beta cell autoantibodies, vitamin D studies, serum cytokines, and flow cytometry with staining for CD3, CD4, CD8, CD25, CD62L, CD45RA, and FOXP3 performed as previously described [2]. Lipid fractions were obtained from whole blood by a modification of Bligh and Dyer [7]. Fatty acids present were converted to methyl esters [8] and analyzed by gas chromatography (model HP6890; Hewlett-Packard, Wilmington, DE) using a CP-WAX column (Varian, Walnut Creek, CA) with mass spectral detection in electron impact mode.

Subjects randomized to therapy had peripheral blood and an aliquot of UCB shipped to the University of Florida for infectious disease testing, HLA confirmation, and viability screening. Thereafter, the UCB unit of qualified subjects was shipped to the University of Florida and stored until infusion. A detailed description of our UCB infusion protocol was previously published [1].

Subjects received pretreatment with diphenhydramine and acetaminophen. No other preparative therapy was given. Thawed UCB cells were infused through a peripheral intravenous line over 10 to 20 minutes. After UCB infusion, subjects randomized to treatment began a regimen of oral vitamin D (2000 IU/day), given as 1 drop of vitamin D3 (2000 IU per drop; Carlson Laboratories, Woodbridge, Ontario, Canada), and oral DHA (38 mg/kg/day) given as 200-mg gel caps (Martek Biosciences Corporation, Columbia, MD). All subjects returned for follow-up testing (identical to baseline) at 3 months, 6 months, and 1 year.

Statistical Analysis

Because outliers in some variables were expected, nonparametric methods were used for all analyses. Because this is a pilot trial, where Type I errors are as serious as Type II errors, no control for study-wide Type I error was made. Within each treatment group, comparisons for changes from baseline with month 12 were performed via the two-sided Wilcoxon signed rank test. Comparisons for between-treatment changes from baseline with month 12 were performed via the two-sample, two-sided Wilcoxon rank test. Descriptive statistics are given as median (50th percentile) and quartiles (25th and 75th percentile). Sample sizes were not based on a power computation but on constraints of funding and subject availability. For descriptive purposes, $P < .05$ was considered to be significant, but actual P values are provided.

RESULTS

Baseline and longitudinal postinfusion characteristics for all subjects are provided in Table 1. Between April 22, 2009 and August 31, 2010, 15 eligible children with type 1 diabetes were randomized (10 treated and 5 control subjects). Five control subjects (3 boys), median age 6.6 years, received intensive diabetes management alone. Ten treated subjects (8 boys), median age 7.2 years, received a single autologous UCB transfusion. All aliquots of UCB had negative Gram stains, and none grew pathogenic organisms when cultured for virus, bacteria, or fungus. One subject developed a cough during infusion that was assessed as a mild infusion reaction and was treated with 20 mg i.v. diphenhydramine. No other adverse events were observed in association with autologous UCB infusion.

Median time from diagnosis to screening was 119 days in the 10 treated children and 106 days in the 5 control subjects. The median infused total nucleated cell count was 1.1×10^7 cells/kg (0.4×10^7 and 3.9×10^7 , respectively; $N = 10$). Median viability was 92.5% (90% and 98%, respectively; $N = 10$). After UCB infusion, subjects randomized to treatment received 1 year of daily oral supplementation with DHA (38 mg/kg/day) and vitamin D (2000 IU/day). Based on capsule counts, DHA compliance was estimated at 91%.

HbA_{1c} remained statistically unchanged ($P = .4$) in both groups throughout the study, with excellent control evidenced by the mean HbA_{1c} of 7.3% at the 1-year visit. Insulin requirements increased significantly in both groups ($P = .001$), although they did not differ significantly when performing between-group comparisons ($P = .18$).

Among treated subjects, area under the curve (AUC) C-peptide at the time of UCB infusion was 0.30 pmol/mL per 120 minutes (interquartile ratio), whereas control subjects

demonstrated baseline AUC C-peptide of 0.55 pmol/mL per 120 minutes. AUC C-peptide declined at all subsequent study visits for both groups compared with baseline ($P < .01$, baseline to 1 year) (Table 1). In addition, although the absolute rate of C-peptide decline was slower in treated (0.23 pmol/mL per 120 minutes) versus control subjects (0.33 pmol/mL per 120 minutes), differences in change of AUC C-peptide between treated and control subjects did not reach significance at 1 year ($P = .29$). Peak C-peptide data demonstrated a similar pattern (Table 1).

When compared with baseline, vitamin D levels were not statistically different at 1 year when evaluating patients who received vitamin D supplementation. However, control subjects demonstrated significant declines in vitamin D levels ($P = .05$), and the intergroup comparison was also significant ($P = .01$).

Fatty acid analysis revealed significant increases among treated subjects treated with DHA ($P = .01$), docosapentaenoic acid ($P = .009$), and eicosapentaenoic acid ($P = .01$) when compared with control subjects. No significant changes were observed in Treg frequency, CD4/CD8 ratio (Table 1), or cytokines and beta cell autoantibodies (data not shown).

DISCUSSION

In contrast to our initial studies of autologous UCB therapy in patients with type 1 diabetes, this protocol required that subjects demonstrate mixed meal tolerance test–stimulated C-peptide >2 pmol/L. Despite the requirement for (at least minimal) endogenous beta cell function, the small sample size in this follow-up pilot study limited our capacity to demonstrate C-peptide preservation after combination therapy with autologous UCB, vitamin D, and DHA.

In addition to the limitation imparted by the relatively small number of study subjects, the capacity to preserve beta cell function may actually be limited by a number of factors. First, an insufficient number of cells that carried regenerative or immunoregulatory capacity may have been transferred to patients with type 1 diabetes. Second, the ongoing autoimmune response in subjects with new-onset type 1 diabetes may contain memory T cells, which are refractive to regulation by Tregs [9], that facilitate the ongoing autoimmune destruction of endogenous or de novo beta cells. Third, vitamin D and DHA, chosen as adjunct therapies largely because of their very-low-risk profiles, may lack the immunomodulatory capacity to provide meaningful treatment in the face of a well-established autoimmune attack.

To address the first issue, efforts are underway to isolate and expand specific cell populations within UCB to augment their therapeutic potential. As proof of concept, a phase I clinical trial is currently underway in adult patients with recent-onset type 1 diabetes using autologous expanded Tregs isolated from peripheral blood (NCT01210664). In terms of the second and third limitations, studies from our laboratory suggest that a therapeutic approach involving transient immune depletion and subsequent induction of immune regulation using a combination of low-dose thymoglobulin and pegylated granulocyte colony-stimulating factor is optimal [10]. As such, we believe that therapies combining transient immune depletion (using thymoglobulin or similar agents) and subsequent infusion of expanded UCB Tregs with or without additional stem cell mobilizing agents may more effectively reset the balance of regulatory and effector T cells in type 1 diabetes. Such approaches will undoubtedly require ongoing discussion regarding equipoise

when being considered as options for the treatment of type 1 diabetes in young children.

Although the combination of UCB infusion, vitamin D, and DHA did not demonstrate C-peptide preservation in this underpowered study, the potential of UCB to participate as a meaningful component in type 1 diabetes intervention therapies remains. Given the very small sample size used in this pilot study, we must be careful to avoid the assumption that a lack of statistical significance implies that cord blood therapies are incapable of providing benefit in type 1 diabetes. Indeed, as rates for autologous cord blood banking climb, we suspect that larger studies can and should follow our efforts. Strong scientific rationale for autologous UCB therapies remains. As such, additional efforts to use autologous UCB in the treatment of type 1 diabetes will continue, with emphasis on improved understanding of UCB Treg function and the potential use of expanded autologous UCB Tregs either alone or in combination with other immunomodulatory agents.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the stem cell laboratory staff and nurses, the Clinical Research Center staff and nurses, and, most important, the children and families who participated in this phase I trial. This study is filed under Clinical Trials Identifier NCT00873925.

Financial disclosure: Supported by the Juvenile Diabetes Research Foundation (JDRF) innovative grant 1-2005-362, JDRF center grant 4-2007-1065, National Institutes of Health (NIH) contract M01RR00082, and NIH grant 1R21DK077580-01. The University of Florida CTSI is supported in part by NIH award UL1TR000064 from the National Center for Advancing Translational Science. DHA was donated by Martek Biosciences Corporation. The sponsors of the study had no role in the study design, data collection, data analysis, interpretation of data, or writing of the report. M.J.H. takes full responsibility for the content of this manuscript.

Conflict of interest statement: There are no conflicts of interest to report.

Authorship statement: M.J.H. designed the study, researched the data, and wrote the manuscript. C.H.W. researched the data and contributed to the discussion. M.A.H., M.C., T.M.B., K.M.M., T.M.S., J.R.W., D.W.D., R.F., J.J.S., M.A.A., and D.A.S. researched the data. T.M.B. researched the data and wrote the manuscript. J.J.S. performed the statistical analysis, assisted in the study design, and edited the manuscript. M.A.A. edited the manuscript. D.A.S. edited the manuscript and contributed to the discussion.

REFERENCES

- Haller MJ, Wasserfall CH, Hulme MA, et al. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. *Diabetes Care*. 2011;34:2567–2569.
- Haller MJ, Wasserfall CH, McGrail KM, et al. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. *Diabetes Care*. 2009;32:2041–2046.
- Haller MJ, Viener HL, Wasserfall C, et al. Autologous umbilical cord blood infusion for type 1 diabetes. *Exp Hematol*. 2008;36:710–715.
- Driscoll KA, Johnson SB, Schatz DA, et al. Use of a precious resource: Parental decision making about using autologous umbilical cord blood in studies involving young children with type 1 diabetes. *Contemp Clin Trials*. 2011;32:524–529.
- Antico A, Tampoia M, Tozzoli R, et al. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. *Autoimmun Rev*. 2012;12:127–136.
- Miller MR, Seifert J, Szabo NJ, et al. Erythrocyte membrane fatty acid content in infants consuming formulas supplemented with docosahexaenoic acid (DHA) and arachidonic acid (ARA): An observational study. *Matern Child Nutr*. 2010;6:338–346.

7. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol*. 1959;37:911–917.
8. Maxwell RJ, Marmer WN. Systematic protocol for the accumulation of fatty acid data from multiple tissue samples: Tissue handling, lipid extraction and class separation, and capillary gas chromatographic analysis. *Lipids*. 1983;18:453–459.
9. Schneider A, Rieck M, Sanda S, et al. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. *J Immunol*. 2008;181:7350–7355.
10. Parker MJ, Xue S, Alexander JJ, et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. *Diabetes*. 2009;58:2277–2284.

Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis

Madan Jagasia^{1,*}, Hildegard Greinix^{2,†}, Marie Robin³, Emma Das-Gupta^{4,†}, Ryan Jacobs¹, Bipin N. Savani¹, Brian G. Engelhardt¹, Adetola Kassim¹, Nina Worel², Robert Knobler², Nigel Russell⁴, Gerard Socie^{3,†}

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

² Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

³ Service d'Hématologie-Greffe de Moelle, Saint Louis Hospital, Paris, France

⁴ University of Nottingham, Division of Epidemiology and Public Health, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

Article history:

Received 28 February 2013

Accepted 18 April 2013

Key Words:

Acute graft-versus-host disease
Steroid-refractory
Extracorporeal photopheresis
Allogeneic hematopoietic cell transplantation

ABSTRACT

The optimal therapy for steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is undefined. We studied patients with SR aGVHD, comparing extracorporeal photopheresis (ECP; $n = 57$) and anticytokine therapy ($n = 41$). In multivariate analyses, ECP, adjusted for steroid dose (odds ratio, 3.42; $P = .007$), and grade >II aGVHD (odds ratio, 68; $P < .001$) were independent predictors of response. ECP therapy, adjusted for conditioning regimen intensity and steroid dose, was associated with superior survival (hazard ratio [HR], 4.6; $P = .016$) in patients with SR grade II aGVHD. Grade >II aGVHD at onset of salvage therapy (HR, 9.4; $P < .001$) and lack of response to therapy (HR, 3.09; $P = .011$) were associated with inferior survival. These findings require validation in a prospective randomized study.

© 2013 American Society for Blood and Marrow Transplantation.

INTRODUCTION

Graft-versus-host disease (GVHD) remains an important complication of allogeneic stem cell transplantation (allo-SCT). Despite prophylaxis, International Bone Marrow Transplantation Registry severity index grade B–D acute GVHD (aGVHD) occurs in 39%–59% of patients undergoing T cell–replete related or unrelated donor allo-SCT [1]. Corticosteroids are the cornerstone of initial therapy for ≥grade II or grade B–D aGVHD [2–4], leading to complete response (CR) in 25%–69% of patients [5,6]. Patients not responding to steroids have a dismal prognosis, with poor survival [2,7].

Numerous agents for treating steroid-refractory (SR) aGVHD have been studied [7,8]. The French group published its experience in a cohort of 93 patients with SR aGVHD using either inolimumab or etanercept [9]. Single-center studies have suggested extracorporeal photopheresis (ECP) using UV-A irradiation of peripheral blood mononuclear cells after incubation with 8-methoxypsoralen as effective treatment

for SR aGVHD [10–12]. The outcomes of ECP and anticytokine therapy have not been compared previously. In the present study, we performed a retrospective comparison of the efficacy of second-line therapy in 98 patients treated with either ECP ($n = 57$) or anticytokine therapy ($n = 41$).

METHODS

Consecutive patients undergoing allo-SCT after January 2005 and developing grade ≥II (according to modified Glucksberg criteria [13]) SR aGVHD (defined as progression after 3 days or no response after 7 days of initial therapy) and treated with ECP (Nashville, Tennessee, USA, $n = 13$; Nottingham, UK, $n = 19$; Vienna, Austria, $n = 25$) or with anticytokine therapy (Paris, France, $n = 41$) were included. Other inclusion criteria were corticosteroids at a dose of at least ≥ 1 mg/kg/day alone as first-line therapy for aGVHD with continuation of calcineurin inhibitors. Anticytokine therapy consisted of inolimumab or etanercept (after 2003). Given that the ECP cohort was recruited after 2005, only a subset of patients from the French dataset (41 patients with SR aGVHD treated with inolimumab or etanercept after 2005) was included in the non-ECP group [9]. ECP was initiated at a frequency of 2–3 treatments per week on a weekly or biweekly basis. ECP therapy was stopped after maximal response was achieved (Austria and UK) or was tapered gradually (Tennessee, USA).

Response was defined as CR (disappearance of signs of GVHD from all organs involved), partial response (PR; any improvement in GVHD), or progressive disease (no response or worsening of GVHD in at least 1 organ). The use of additional immunosuppressive agents after ECP or anticytokine therapy for controlling aGVHD was considered progressive disease. Response was assessed at 4 weeks after anticytokine therapy or at the end of ECP (a median of 45 days after the start of ECP). Given the variability of response assessment and retrospective nature of the analyses, the primary focus of this analysis was overall survival (OS).

Descriptive statistics were calculated and groups were compared using the chi-squared test (nominal) and Wilcoxon rank-sum test (continuous) respectively. Two-proportion tests were used to compare stage of GVHD before and after therapy. OS was measured from the initiation of ECP or anticytokine therapy using Kaplan-Meier survival curves and compared

[†] M.J., H.G., E.D.-G., and G.S. contributed equally to this work.

Preliminary data from this study were presented at the Annual Meeting of the European Group for Blood and Marrow Transplantation in Geneva, Switzerland, April 1–4, 2012.

Financial disclosure: See Acknowledgments on page 1132.

* Correspondence and reprint requests: Madan Jagasia, 3973 TVC, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232-5505.

E-mail address: madan.jagasia@vanderbilt.edu (M. Jagasia).

1083-8791/\$ — see front matter © 2013 American Society for Blood and Marrow Transplantation.

<http://dx.doi.org/10.1016/j.bbmt.2013.04.018>